Publication at First Faculty of Medicine |
2017
Abstract
We thank Hofstetter and colleagues for their interest in the position paper we published in the Journal of Hypertension on behalf of the European Society of Hypertension. We agree with their point that there is no obvious reason why among the 15 polypills under development, the vast majority, that is 13, include an angiotensin-converting enzyme inhibitor (ACEI) and only two assign to an AT1 blockers (ARB) the blood pressure (BP) lowering component of a polypill.